Suitability:
This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.
We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in multi cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.
But if you do invest, you must do so only through the SIP route. Click here to read a primer on SIP investing.
Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.
Taxability of earnings:
Capital gains
Dividends
Please wait...
Please wait...
| YTD | 1-Day | 1-W | 1-M | 3-M | 6-M | 1-Y | 3-Y | 5-Y | 7-Y | 10-Y | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund | -0.60 | 3.92 | 8.49 | -7.01 | -1.69 | 4.58 | 1.41 | -0.32 | -- | -- | -- |
| S&P BSE Healthcare TRI | -7.34 | 3.56 | 6.59 | -10.83 | -8.38 | 0.86 | -11.92 | -6.41 | -- | -- | -- |
| Equity: Sectoral-Pharma | -2.86 | 3.17 | 6.33 | -8.91 | -3.81 | 6.03 | -0.34 | -1.73 | -- | -- | -- |
| Rank within category | 1 | 2 | 1 | 1 | 1 | 8 | 4 | 2 | -- | -- | -- |
| Number of funds in category | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 4 | 3 | 3 | 3 |
As on 03-Apr-2020
| Best (Period) | Worst (Period) | |
|---|---|---|
| Week | 8.49 (27-Mar-2020 - 03-Apr-2020) | -11.13 (05-Mar-2020 - 12-Mar-2020) |
| Month | 10.33 (20-Jul-2018 - 21-Aug-2018) | -18.44 (20-Feb-2020 - 23-Mar-2020) |
| Quarter | 22.21 (05-Jun-2018 - 04-Sep-2018) | -14.66 (26-Sep-2016 - 26-Dec-2016) |
| Year | 22.48 (06-Sep-2017 - 06-Sep-2018) | -18.70 (08-Sep-2016 - 08-Sep-2017) |
| Mean | Std Dev | Sharpe | Sortino | Beta | Alpha | |
|---|---|---|---|---|---|---|
| Fund | 0.55 | 15.73 | -0.32 | -0.45 | 0.82 | 3.97 |
| S&P BSE Healthcare TRI | -5.34 | 18.13 | -0.60 | -1.07 | -- | -- |
| Equity: Sectoral-Pharma | -0.97 | 15.89 | -0.40 | -0.64 | 0.83 | 2.57 |
| Rank within category | 2 | 2 | 2 | 2 | 2 | 2 |
| Number of funds in category | 4 | 4 | 4 | 4 | 4 | 4 |
The Risk Measures have been calculated using calendar month returns for the last three years.
As on 31-Mar-2020
Please wait...
| Number of Stocks | 17 |
| Top 10 Stocks (%) | 84.83 |
| Top 5 Stocks (%) | 56.20 |
| Top 3 Sectors (%) | 99.48 |
| Portfolio P/B Ratio | 3.86 |
| Portfolio P/E Ratio | 30.63 |
| Fund | Category | |
|---|---|---|
| Average Mkt Cap (Rs Cr) | 27,556 | 22,876 |
| Giant (%) | -- | 1.78 |
| Large (%) | 48.32 | 37.31 |
| Mid (%) | 39.65 | 48.19 |
| Small (%) | 12.03 | 14.30 |
| Tiny (%) | -- | -- |
Please wait...
| Company | Sector | P/E | 3Y High | 3Y Low | % Assets | |
|---|---|---|---|---|---|---|
|
Dr. Reddy's Lab | Healthcare | 30.73 | 15.59 | 0.00 | 15.58 |
|
Abbott India | Healthcare | 56.51 | 11.41 | 1.74 | 11.41 |
|
Divi's Laboratories | Healthcare | 39.72 | 10.58 | 0.00 | 10.58 |
|
|
Sun Pharmaceutical Inds. | Healthcare | 22.54 | 23.13 | 5.93 | 10.51 |
|
|
Lupin | Healthcare | -- | 12.20 | 0.00 | 8.13 |
|
|
Ipca Laboratories | Healthcare | 28.27 | 11.01 | 2.32 | 7.82 |
|
|
Procter & Gamble Health | Healthcare | 40.41 | 7.30 | 0.00 | 6.57 |
|
|
Apollo Hospitals | Healthcare | 51.64 | 6.51 | 1.51 | 6.51 |
|
|
Alkem Laboratories | Healthcare | 24.54 | 6.44 | 0.00 | 3.92 |
|
|
Alembic Pharmaceuticals | Healthcare | 13.92 | 6.16 | 3.81 | 3.81 |
|
|
Cadila Healthcare | Healthcare | 22.62 | 8.35 | 0.00 | 3.41 |
|
|
Aurobindo Pharma | Healthcare | 8.73 | 8.81 | 1.53 | 3.06 |
|
|
Healthcare Global Enterprises | Healthcare | -- | 5.13 | 0.00 | 2.75 |
|
Narayana Hrudayalaya | Healthcare | 37.80 | 1.86 | 0.00 | 1.86 |
|
|
Syngene International | Healthcare | 25.65 | 7.99 | 0.00 | 1.51 |
|
|
Dr. Lal Pathlabs | Healthcare | 46.39 | 2.59 | 0.00 | 1.28 |
|
|
Astrazeneca Pharma India | Healthcare | 82.94 | 0.80 | 0.00 | 0.78 |
Indicates an increase or decrease or no change in holding since last portfolio
Indicates a new holding since last portfolio
As on 29-Feb-2020
— Sailesh Jain since 09-Nov-2018
Education: Mr. Jain is a Commerce Graduate and an MBA.
Experience: Prior to joining TATA Mutual Fund, he has worked with Invesco Mutual Fund, IDFC Securities Ltd. as Head Derivatives, Quant Broking Pvt Ltd. as Vice President and IIFL(India Infoline) as Vice President.
Funds Managed:
— Meeta Shetty since 09-Nov-2018
Education: Ms. Shetty is Bachelor in Economics and CFA Charterholder
Experience: Prior to joining TATA Mutual Fund, she has worked with Kotak Securities, HDFC Securities, AMSEC(Asian Market Securities), Dalal & Broacha Stock Broking and karvey Stock Broking.
Funds Managed:
Personal finance advice and mutual fund ideas delivered to your inbox every Monday
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
| Minimum Investment (₹) | 5,000 |
| Minimum Addl Investment (₹) | 1,000 |
| Minimum SIP Investment (₹) | 150 |
| Minimum No of Cheques | 12 |
| Minimum Withdrawal (₹) | 500 |
| Minimum Balance (₹) | 500 |
| Exit Load | 0.25% for redemption within 91 days |
| Fund House: | Tata Mutual Fund |
| Launch Date: | 28-Dec-2015 |
| Return Since Launch: | -2.06% |
| Benchmark: | NIFTY Pharma TRI |
| Riskometer: | High |
| Type: | Open-ended |
| Assets: | ₹ 165 Cr (As on 29-Feb-2020) |
| Expense: | 2.54% (As on 29-Feb-2020) |
| Risk Grade: | -- |
| Return Grade: | -- |
| Turnover: | 32.11% |
AMC: Tata Asset Management Private Ltd
Address: 9th Floor, Mafatlal Centre, Nariman Point, Mumbai - 400021
Phone: 1800-209-0101
Email: [email protected]
Website: www.tatamutualfund.com
Registrar & Transfer Agent: Computer Age Management Services Ltd.
Address: 7th Floor, Tower II, Rayala Towers, 158, Anna Salai, Chennai - 600002
Phone: 1800-3010-6767 / 1800-419-7676
Fax: 044-30407101
Email: [email protected]
Website: www.camsonline.com
Friday, 20-Mar-2020
12:30 PM - 01:00 PM
Registration Over
